CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 7 filers reported holding CRISPR THERAPEUTICS AG in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,400,000 | -20.9% | 96,935 | -2.1% | 0.00% | 0.0% |
| Q2 2023 | $5,560,000 | +27.8% | 99,033 | +2.9% | 0.00% | 0.0% |
| Q1 2023 | $4,352,000 | +7.5% | 96,242 | -3.4% | 0.00% | 0.0% |
| Q4 2022 | $4,048,000 | -53.9% | 99,606 | -25.9% | 0.00% | -66.7% |
| Q3 2022 | $8,780,000 | -35.9% | 134,371 | -40.4% | 0.00% | -25.0% |
| Q2 2022 | $13,705,000 | -9.8% | 225,517 | -6.8% | 0.00% | 0.0% |
| Q1 2022 | $15,189,000 | -15.9% | 241,983 | +1.5% | 0.00% | 0.0% |
| Q4 2021 | $18,061,000 | -32.7% | 238,332 | -0.6% | 0.00% | -42.9% |
| Q3 2021 | $26,846,000 | -29.7% | 239,843 | +1.6% | 0.01% | -30.0% |
| Q2 2021 | $38,201,000 | +36.6% | 235,960 | +2.8% | 0.01% | +25.0% |
| Q1 2021 | $27,975,000 | -17.7% | 229,588 | +3.4% | 0.01% | -20.0% |
| Q4 2020 | $34,007,000 | +100.6% | 222,113 | +9.6% | 0.01% | +66.7% |
| Q3 2020 | $16,952,000 | +28.9% | 202,672 | +13.3% | 0.01% | +20.0% |
| Q2 2020 | $13,151,000 | +170.4% | 178,942 | +56.1% | 0.01% | +150.0% |
| Q1 2020 | $4,863,000 | -26.2% | 114,657 | +5.9% | 0.00% | 0.0% |
| Q4 2019 | $6,593,000 | +51.7% | 108,237 | +2.1% | 0.00% | 0.0% |
| Q3 2019 | $4,346,000 | -23.4% | 106,031 | -12.0% | 0.00% | 0.0% |
| Q2 2019 | $5,672,000 | +130.9% | 120,425 | +75.1% | 0.00% | +100.0% |
| Q1 2019 | $2,456,000 | +43.8% | 68,760 | +15.0% | 0.00% | 0.0% |
| Q4 2018 | $1,708,000 | -49.8% | 59,787 | -22.1% | 0.00% | 0.0% |
| Q3 2018 | $3,404,000 | +7.5% | 76,758 | +42.4% | 0.00% | 0.0% |
| Q2 2018 | $3,167,000 | +160.2% | 53,892 | +102.4% | 0.00% | 0.0% |
| Q1 2018 | $1,217,000 | +274.5% | 26,620 | +91.9% | 0.00% | – |
| Q4 2017 | $325,000 | +132.1% | 13,869 | +76.7% | 0.00% | – |
| Q3 2017 | $140,000 | +164.2% | 7,850 | +136.1% | 0.00% | – |
| Q2 2017 | $53,000 | -28.4% | 3,325 | -1.5% | 0.00% | – |
| Q1 2017 | $74,000 | – | 3,376 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |